• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Dysfunctional Uterine Bleeding Companies

    ID: MRFR/Pharma/3264-HCR
    110 Pages
    Rahul Gotadki
    October 2025

    "Dysfunctional Uterine Bleeding" (DUB) is a medical term that refers to abnormal uterine bleeding that is not associated with any structural abnormalities or underlying medical conditions. Instead, it is often attributed to hormonal imbalances that disrupt the normal menstrual cycle. Companies that may be involved in addressing or providing solutions for Dysfunctional Uterine Bleeding typically operate in the healthcare and pharmaceutical sectors.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Dysfunctional Uterine Bleeding Market

    Dysfunctional Uterine Bleeding Key Companies

     

    Latest Dysfunctional Uterine Bleeding Companies Update


    Myovant's Ormeloxifene (SER-120) Phase 3 Trials is conducting two Phase 3 trials (MUSE 1 and MUSE 2) evaluating the efficacy and safety of Ormeloxifene (SER-120) for the treatment of DUB caused by fibroids. Positive results could significantly impact the market by offering a non-hormonal therapy option.


    Minerva Surgical's Sonata® System received FDA approval for its Sonata® System, a minimally invasive device for endometrial ablation used in the treatment of heavy menstrual bleeding and DUB. This technology offers an alternative to traditional hysterectomy for some patients.


    List of Dysfunctional Uterine Bleeding Key Companies in the Market



    • Braun Melsungen AG (Germany)

    • Hologic Inc. (U.S.)

    • Karl Storz Gmbh & Co. KG (Germany)

    • Medgyn Products Inc.

    • Olympus (Japan)

    • Richard Wolf GmbH (Germany)

    • Stryker (U.S.)

    • Xion Medical GmbH (Germany)

    • Cadila Pharmaceuticals Ltd. (India)

    • Torrent Phamraceuticals (India)